WO2007120787A3 - Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression - Google Patents

Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression Download PDF

Info

Publication number
WO2007120787A3
WO2007120787A3 PCT/US2007/009063 US2007009063W WO2007120787A3 WO 2007120787 A3 WO2007120787 A3 WO 2007120787A3 US 2007009063 W US2007009063 W US 2007009063W WO 2007120787 A3 WO2007120787 A3 WO 2007120787A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
treating
liv
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/009063
Other languages
French (fr)
Other versions
WO2007120787A2 (en
Inventor
Mary J Jantapour
Guoying Yu
Robert To
Vivien Chan
Deborah Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0710616-5A priority Critical patent/BRPI0710616A2/en
Priority to US12/296,833 priority patent/US20100196377A1/en
Priority to CA002650126A priority patent/CA2650126A1/en
Priority to EP07755364A priority patent/EP2012827A2/en
Priority to JP2009505486A priority patent/JP2009541208A/en
Priority to AU2007238636A priority patent/AU2007238636A1/en
Priority to MX2008013121A priority patent/MX2008013121A/en
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of WO2007120787A2 publication Critical patent/WO2007120787A2/en
Anticipated expiration legal-status Critical
Priority to TNP2008000401A priority patent/TNSN08401A1/en
Priority to NO20084795A priority patent/NO20084795L/en
Publication of WO2007120787A3 publication Critical patent/WO2007120787A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides, inter alia, methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with LIV-1 overexpression.
PCT/US2007/009063 2006-04-13 2007-04-12 Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression Ceased WO2007120787A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US12/296,833 US20100196377A1 (en) 2006-04-13 2007-04-12 Methods of treating, diagnosing or detecting cancer
CA002650126A CA2650126A1 (en) 2006-04-13 2007-04-12 Methods of treating, diagnosing or detecting cancer
EP07755364A EP2012827A2 (en) 2006-04-13 2007-04-12 Methods of treating, diagnosing or detecting cancer
JP2009505486A JP2009541208A (en) 2006-04-13 2007-04-12 How to treat, diagnose, or detect cancer
AU2007238636A AU2007238636A1 (en) 2006-04-13 2007-04-12 Methods of treating, diagnosing or detecting cancer
BRPI0710616-5A BRPI0710616A2 (en) 2006-04-13 2007-04-12 methods to treat, diagnose or detect cancer
MX2008013121A MX2008013121A (en) 2006-04-13 2007-04-12 Methods of treating, diagnosing or detecting cancer.
TNP2008000401A TNSN08401A1 (en) 2006-04-13 2008-10-13 Methods of treating diagnosing or detecting cancer
NO20084795A NO20084795L (en) 2006-04-13 2008-11-13 Procedure for treating, diagnosing or detecting cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79187106P 2006-04-13 2006-04-13
US60/791,871 2006-04-13

Publications (2)

Publication Number Publication Date
WO2007120787A2 WO2007120787A2 (en) 2007-10-25
WO2007120787A3 true WO2007120787A3 (en) 2009-04-30

Family

ID=38610188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009063 Ceased WO2007120787A2 (en) 2006-04-13 2007-04-12 Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression

Country Status (15)

Country Link
US (1) US20100196377A1 (en)
EP (2) EP2012827A2 (en)
JP (1) JP2009541208A (en)
KR (1) KR20090010194A (en)
CN (1) CN101622273A (en)
AU (1) AU2007238636A1 (en)
BR (1) BRPI0710616A2 (en)
CA (1) CA2650126A1 (en)
MA (1) MA30393B1 (en)
MX (1) MX2008013121A (en)
NO (1) NO20084795L (en)
TN (1) TNSN08401A1 (en)
TW (1) TW200813231A (en)
WO (1) WO2007120787A2 (en)
ZA (1) ZA200808669B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
EP2493916B1 (en) * 2009-10-26 2016-06-08 Externautics S.p.A. Lung tumor markers and methods of use thereof
JP6105481B2 (en) * 2010-12-06 2017-03-29 シアトル ジェネティクス，インコーポレーテッド Humanized antibodies against LIV-1 and their use for cancer therapy
US9310353B2 (en) * 2014-02-27 2016-04-12 The Procter & Gamble Company Method for evaluating bioavailable zinc
KR20160045471A (en) 2014-10-17 2016-04-27 대산안전산업 주식회사 Soundproof panel
MA45324A (en) 2016-03-15 2019-01-23 Seattle Genetics Inc POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT
MA50943A (en) * 2017-12-01 2020-10-07 Seattle Genetics Inc HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF BREAST CANCER
CN111289756A (en) * 2018-12-10 2020-06-16 北京师范大学 Urine marker related to lung metastasis and tumor formation of ovarian cancer
GB201908208D0 (en) * 2019-06-10 2019-07-24 Univ College Cardiff Consultants Ltd An anti-mitotic agent
WO2021047507A1 (en) * 2019-09-09 2021-03-18 浙江百寿康迪生物医药有限责任公司 Method for identifying substance capable of affecting aging

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055178A2 (en) * 2000-01-25 2001-08-02 Genentech, Inc. Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
WO2004066933A2 (en) * 2003-01-27 2004-08-12 Biogen Idec Ma Inc. Compositions and methods for treating cancer using igsf9 and liv-1
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2005063301A1 (en) * 2003-12-26 2005-07-14 Toshio Hirano Emt inducer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE120454T1 (en) 1988-06-14 1995-04-15 Cetus Oncology Corp COUPLING AGENT AND STERICALLY HINDERED CONJUGATES THEREOF BOUND WITH DISULFIDE.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (en) 1990-08-29 2005-08-15 Genpharm Int TRANSGENIC MICE CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
DE69133036T2 (en) 1990-11-09 2003-02-06 Stephen D. Gillies CYTOKINE IMMUNOCONJUGATE
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
MD1367C2 (en) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Methods of B-cells lymphoma treatment, anti-CD20 antibodies, hybridoma
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2132500A1 (en) * 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
PL3524611T3 (en) 2003-05-20 2021-06-14 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055178A2 (en) * 2000-01-25 2001-08-02 Genentech, Inc. Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
WO2004066933A2 (en) * 2003-01-27 2004-08-12 Biogen Idec Ma Inc. Compositions and methods for treating cancer using igsf9 and liv-1
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2005063301A1 (en) * 2003-12-26 2005-07-14 Toshio Hirano Emt inducer
EP1709976A1 (en) * 2003-12-26 2006-10-11 Toshio Hirano Emt- inducing agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHOWANADISAI W ET AL: "Zinc deficiency is associated with increased brain zinc import and LIV-1 expression and decreased ZnT-1 expression in neonatal rats", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 135, no. 5, May 2005 (2005-05-01), pages 1002 - 1007, XP001207366, ISSN: 0022-3166 *
KASPER G ET AL: "Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients", INTERNATIONAL JOURNAL OF CANCER, vol. 117, no. 6, December 2005 (2005-12-01), pages 961 - 973, XP002457315, ISSN: 0020-7136 *
TAYLOR K M ET AL: "Zinc transporter LIV-1: a link between cellular development and cancer progression", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 15, no. 10, December 2004 (2004-12-01), pages 461 - 463, XP004640893, ISSN: 1043-2760 *
WIMMER U ET AL: "Two major branches of anti-cadmium defense in the mouse: MTF-1/metallothioneins and glutathione", NUCLEIC ACIDS RESEARCH, vol. 33, no. 18, 2005, pages 5715 - 5727, XP002457325, ISSN: 0305-1048 *
YAMASHITA S ET AL: "Zinc transporter LIV1 controls epithelial-mesenchymal transition in zebrafish gastrula organizer", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 429, 20 May 2004 (2004-05-20), pages 298 - 302, XP002990283, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
EP2407483A1 (en) 2012-01-18
JP2009541208A (en) 2009-11-26
US20100196377A1 (en) 2010-08-05
WO2007120787A2 (en) 2007-10-25
KR20090010194A (en) 2009-01-29
BRPI0710616A2 (en) 2011-08-16
NO20084795L (en) 2009-01-13
EP2012827A2 (en) 2009-01-14
CN101622273A (en) 2010-01-06
CA2650126A1 (en) 2007-10-25
AU2007238636A1 (en) 2007-10-25
MX2008013121A (en) 2009-03-25
MA30393B1 (en) 2009-05-04
TW200813231A (en) 2008-03-16
ZA200808669B (en) 2009-10-28
TNSN08401A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2009036427A3 (en) Prostate cancer biomarkers
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
WO2007061874A3 (en) Methods and compositions for use in treating cancer
WO2006089125A3 (en) Methods of detecting ovarian cancer
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2007134210A3 (en) Methods and compositions for the diagnosis and treatment of cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
WO2008008923A3 (en) Compositions and methods for targeting cancer-specific transcription complexes
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2008070472A3 (en) Use of plasma hsp90 related to malignancy
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2007056049A3 (en) Molecular profiling of cancer
WO2008092002A3 (en) Compositions and methods for treating and diagnosing pancreatic cancer
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2008134020A8 (en) Ccl18 and ccl3 methods and compositions for detecting and treating cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780021878.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07755364

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2650126

Country of ref document: CA

Ref document number: 12008502283

Country of ref document: PH

Ref document number: MX/A/2008/013121

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 194702

Country of ref document: IL

Ref document number: 2008101677

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009505486

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2007238636

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007238636

Country of ref document: AU

Date of ref document: 20070412

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 572588

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007755364

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2008000661

Country of ref document: DZ

Ref document number: 1020087027681

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008144658

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12296833

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0710616

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081013